Supplementary Figures
Supplementary Figure 1 Verification of peroxisome targeting for selected point mutated reporter fusions (a-c) and analysis of peroxisome targeting at very early time points p.t. for two canonical strong PTS1s, SRM> (d) and SRI> (e). Onion epidermal cell were biolistically transformed with EYFP fusion constructs that were C-terminally extended by the decapeptide PTS1 domain of a model sequence, acyl-CoA oxidase isoform 4 from Zinnia elegans (ZeACX4, VAKTTRP-SRV>) or various mutant versions. Subcellular targeting was analyzed by fluorescence microscopy at different time intervals post transformation (p.t.). The mutated aa are underlined. Peroxisome targeting was verified by colocalization of EYFP fluorescence with the peroxisomal marker DsRed-SKL for the original model sequence (see Fig. 1b ) and the PTS1 tripeptide point mutations from SRV> to SRI> (a), to SRM> (b) and to SRY> (c). To investigate putative peroxisome targeting efficiencies for the two canonical strong PTS1 domains terminating with SRM> and SRI> and document the efficiency of peroxisome targeting, peroxisome targeting was investigated at very early time points p.t. (4 h, 8 h, 12 h and 24 h). The EYFP images were not modified for brightness or contrast in single transformants (d and e). Tables   Supplementary Table I :PWM Scoring Matrix
In the PWM-based PTS1 protein prediction model, each of the 20 possible amino acid (aa) residues of the C-terminal 14-aa positions is assigned a position-specific score, which indicates whether a specific residue at a particular sequence position is predicted to enhance (more positive score) or reduce peroxisome targeting (more negative score) and to what extent.
Position
Res. 
Measurement of Anisotropy.
Anisotropy is a fundamental molecular property which reflects the interaction of a fluorescent molecule with plane polarised light. Low values of anisotropy indicate that the molecule is tumbling rapidly relative to the fluorescence lifetime of the fluorophore whereas higher values of anisotropy indicate that the tumbling times are slow compared to this value. The fluorescence lifetimes of the fluorophores used in this study are typically 1-10 ns and hence low values of anisotropy are shown when the fluorophore is part of a small peptide molecule. However, when the fluorophore labelled peptide binds to the larger protein the tumbling rate is related to the overall complex size and consequently slows significantly with a resulting increase in anisotropy. Anisotropy is an intrinsic molecular property and should be used for the determination of binding constants (rather than the related polarization values Assays were performed using black 384 well plates (Optiplate, PerkinElmer) and the plates were incubated at 25 °C for 20 minutes with agitation (within the plate reader) prior to reading to ensure equilibration. The reading protocol was optimised (instrument gain, read height) using the instrument software to ensure that the detector was not saturated. 30 flashes were used per measurement.
The anisotropy (r) was calculated using Equation 1.
Equation 1
The total fluorescence intensity (I) is defined by Equation 2.
= + 2 Equation 2
Where s is the intensity of the light emitted with the same polarisation as the excitation light, p is the intensity of the light emitted with perpendicular polarisation and g is a grating factor which accounts for the different responsiveness of an instrument to light with differing polarisations. In these assays this was set to 1 as part of the optimisation process.
Blank corrections were performed by subtracting the average of the appropriate blank intensities in the s and p channels prior to calculation of the anisotropy. [2] 
Preparation of Assay Plates
All assays were performed using an FA buffer (HEPES (20 mM), NaCl (150 mM), pH 7.5 with NaOH).
In order to minimise non-specific interactions the plates were pre-treated with a gelatine solution: [3] All wells to be used were filled with 80 µl of FA buffer containing 0.32 mg/ml of gelatine solution using a Multidrop combi (ThermoElectron), sealed using self adhesive plate seals (StarLab) and stored at 4 o C the evening prior to use.
The lissamine rhodamine-YQSKL peptide was stored as a stock solution at 500 µM in H 2 O, stored at either 4 o C as a working stock with dilutions made fresh for each plate or at -80 o C for longer term storage. All stock solutions (protein, lissamine rhodamine-YQSKL and inhibitor) were stored at 4 o C or kept on ice at all times.
Determination of limits of anisotropy
60 µl of gelatine buffer solution was removed from plate rows A-F, wells 1-24. 40 µl of protein stock solution (3x desired concentration) was added to well A1 and the contents of the well agitated with a pipette. 40 µl of solution was removed from A1 and placed in A2, then agitated and placed into A3. Following addition and agitation of column A24, 40 µl of solution was removed and discarded. The above process repeated across the entire series and for Rows B-F. 20 µl of 200 nM of lissamine rhodamine-YQSKL solution in FA Buffer (final concentration 100 nM) was added to all wells in the first three (A-C) rows. 20 µl of FA buffer was then added to the wells of the other three rows (D-F) to act as the blank. The anisotropy of each well was measured and the average intensities measured in wells containing no tracer peptide were used to provide a blank correction for each protein concentration (see section 3.1). The anisotropy was plotted against protein concentration with the standard deviation of the replicates used as the error. The data were fitted to a logistic function (equation 3) to find the lower and upper limits of the anisotropy r max , r min which reflect the anisotropy of the tracer when in the unbound and bound state respectively (Supplementary Figure 2) .
Where is the protein concentration 0 is the midpoint of the transition and p is the slope Across a number of repeats, average values for the limits of anisotropy were found to be r min = 69 r max = 310 for both full length PEX5 and PEX5C and these values were used throughout subsequent assays. These data were also used to check for any change in quantum yield between the bound and free states of the assay by checking for any variation in total intensity (Equation 2) over the course of the titration. No change was observed (data not shown).
Determination of the dissociation constant of the fluorescent tracer.
60 µl of gelatine buffer solution was removed from wells 1-3 of rows A-P. A serial dilution of lissamine rhodamine labelled YQSKL in FA buffer was made starting with 2000 nM (3 x final concentration) and diluted by ½ through a series. 20 µl of each was added to columns 1 -14. 20 µl of FA buffer was added to A15-C15 to act as a blank. 20 µl of a ~300 nM solution of protein in FA buffer was then added to all wells being used (3 x final concentration). The anisotropy was then measured (Section 3.1) and calculated by subtracting the average intensities from the s and p channels in the blank wells from the wells of interest. The anisotropy in each well was converted into the fraction of tracer bound using equation 4 and finally to the amount of tracer bound by multiplying by the total concentration of tracer in the well of interest.
Equation 4
Where is the concentration of fluorescent tracer bound to PEX5, is the total tracer concentration. reflects the difference in quantum yields of the bound and free states which was determined to be 1 (Section 3.
3)
The data were plotted and fitted to equation 5 using non-linear least squares fitting algorithm in OriginPro to determine the K d of the tracer peptide for the protein. The error in K d is obtained from the fitting error within the procedure (Supplementary Figure 3) .
Equation 5
Where is the concentration of fluorescent tracer bound to PEX5, is the total tracer concentration. is the total concentration of PEX5 
Equation 7
Where is the dissociation constant of unlabelled peptide and is the dissociation constant of fluorescent tracer. The remaining parameters are computed using Equations 8-10 0 , the unbound concentration of protein at zero inhibitor concentration is calculated from:
Equation 8
Where is the dissociation constant of fluorescent tracer, is the total tracer concentration. is the total concentration of PEX5 L 50 the concentration of unbound fluorescent tracer at the IC 50 point is calculated from:
Equation 9
Where is the total tracer concentration.
is the total concentration of PEX5 and 0 is the unbound concentration of protein at zero inhibitor concentration calculated from Equation 8
I 50 , the unbound inhibitor concentration at the IC 50 point is calculated from:
Equation 10
Where 50 is determined from the curve fit of inhibitor titration. is the total concentration of PEX5 and is the dissociation constant of fluorescent tracer. 0 is calculated from Equation 8 and 50 
From Equation 9
As the error in the final K i involves components from the error in the measurement of the K d of the tracer and the IC 50 of the inhibitor the error was assessed using simulation. A series of simulations were run with a simulated value of K d and IC 50 generated around the observed mean, the probability of the value occurring was based upon a normal distribution with standard deviation equal to the fitting error of each value. The simulated value was then propagated to give a simulated K i . 2000 simulations were performed with the final error estimated from the standard deviation of the simulated results. The calculated K i and errors are shown in the Table II of the main manuscript.
Peptide Synthesis and Characterisation

General Information
N-terminal Fmoc protected amino acids (Merck Millipore) were used with the following side chain protection: Arg (Pbf), Asn and Gln (Trt), Glu (OtBu) Lys, (N-Boc), Ser, Thr and Tyr (tBu). Peptides were synthesised on 2-Chlorotrityl resin which was purchased pre-loaded with the appropriate Cterminal amino acid. Peptide elongations were performed manually using standard Fmoc solid phase peptide synthesis as outlined by Chan and White (Chan and White, 1999) using SPE tubes fitted with a polyethylene frit (Grace Davidson, Baltimore, USA) and a vacuum tank attached to a water aspirator. DCM, Diethyl ether (Fisher Scientific, Hampton, NH, USA), DIPEA (Sigma-Aldrich), DMF (Fluka, Buchs, Switzerland) HCTU (Merck-Millipore), Piperidine (Fluka) and triisopropylsilane (Sigma-Aldrich) were used without further purification. TFA (Sigma-Aldrich) was freshly distilled before use. Lissamine TM rhodamine B sulfonyl chloride was purchased from Invitrogen (Invitrogen Molecular Probes). Mass spectrometry and LC-MS was performed on a Bruker HCT Ultra spectrometer using an electrospray source. High Resolution accurate mass spectra were obtained on a Bruker MicrOTOF using electrospray ionisation. Analytical HPLC was performed on an Agilent 1290 Infinity LC system and preparative HPLC on a Gilson preparative system. Reverse phase solvents were acetonitrile and Ultra pure water both containing 0.1 % TFA.
General Procedure for Peptide Synthesis
Peptide Assembly
Peptides were prepared on 2 Cl-Trt resin preloaded with the C-terminal amino acid (0.085 mmol, 0.85 mmol/g). The resin was swollen in DCM for 20 mins then washed 2 x 5 mins with DMF. Fmoc amino acid (5 mmol) and HCTU (5 mmol) were dissolved in the minimum volume of DMF. DIPEA (10 mmol) was added and transferred to the tube containing the resin (1 mmol). The mixture was gently agitated for 1 hr on a laboratory rotator and the resin was isolated by filtration and washed with DMF (3 × 5 ml × 2 mins). A negative Kaiser colour test showed a complete reaction. The resin was treated with a solution of 20 % piperidine in DMF (5 × 5 ml × 2 mins) and then washed with DMF (5 × 5 ml × 2 mins). Couplings were repeated until the desired sequence had been assembled. The functionalised resin was washed with DMF (3 × 3 ml, 2 mins), Isopropanol (3 × 3 ml × 5 mins) and hexane (4 × 3 ml × 2 mins), sucked dry on a manifold tank (10 min) then dried in-vacuo over KOH for 16 hrs.
Cleavage of Peptide from resin
The dried functionalised resin was treated with a cleavage cocktail of TFA/H 2 O/TIPS (95:2.5:2.5, 1 ml/25 mg resin) with the exception of Met containing peptides in which case a cocktail of TFA/H 2 O/EDT/TIPS (95:2.5:2.5:1, 1 ml/25 mg resin) was used and all solvents degassed with nitrogen prior to use. The mixture was gently agitated for 1 hr. The resin beads were removed by filtration and rinsed with fresh TFA (2 × 2 ml). The combined filtrates were concentrated under reduced pressure to ~500 µl and the peptide then isolated by precipitation in chilled Et 2 O (5 ml). The peptide was then dissolved in H 2 O until the Et 2 O contained no further precipitate and the aqueous solution then washed with further chilled Et 2 O (2 × 5 ml) then lyophilised. The resulting peptides were purified by preparative reverse phase HPLC, lyophilised and the purity of the peptides confirmed by electrospray MS and analytical HPLC. Recovered yields for the purified peptides are calculated based on the manufactures quoted loading of the resin.
Synthesis of the fluorescent tracer peptide
Fmoc cleaved, side-chain protected resin bearing the sequence YQSKL, (20 mg, 11.2 µmol) was suspended in anhydrous DMF (2 ml) and DIPEA (19.4 µL, 112 µmol, 10 eq) then Lissamine TM rhodamine B sulfonyl chloride (20 mg, 3 eq) was added to the reaction mixture. The reaction was stirred in the dark on ice for 18 hrs under nitrogen. The resin washed with DMF (2 × 3 ml × 2 mins) and DCM (2 × 3 ml × 2 min), then cleaved and purified as detailed in the general method then purified via preparative HPLC to yield a dark pink solid
Characterisation data for peptides
Lissamine Rhodamine-YQSKL-CO 2 H (Fluorescent tracer peptide)
Yield = 2.4 mg, 20 %; RP-HPLC Ascentis Express Peptide (ES -C18, 10 cm x 2.1 mm); Flow rate 0.5 ml min 
H 2 N-YQSKL-CO 2 H
Yield = 33 mg; 62%. RP-HPLC Ascentis Express Peptide (ES -C18, 10 cm x 2.1 mm); Flow rate 0.5 ml min 
H 2 N-VAKTTRPSRI-CO
